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Abstract: Deep-sequencing of the ABCA4 locus has revealed that ~10% of autosomal recessive
Stargardt disease (STGD1) cases are caused by deep-intronic mutations. One of the most recurrent
deep-intronic variants in the Belgian and Dutch STGD1 population is the c.4539+2001G>A mutation.
This variant introduces a 345-nt pseudoexon to the ABCA4 mRNA transcript in a retina-specific
manner. Antisense oligonucleotides (AONs) are short sequences of RNA that can modulate splicing.
In this work, we designed 26 different AONs to perform a thorough screening to identify the most
effective AONs to correct splicing defects associated with c.4539+2001G>A. All AONs were tested
in patient-derived induced pluripotent stem cells (iPSCs) that were differentiated to photoreceptor
precursor cells (PPCs). AON efficacy was assessed through RNA analysis and was based on correction
efficacy, and AONs were grouped and their properties assessed. We (a) identified nine AONs with
significant correction efficacies (>50%), (b) confirmed that a single nucleotide mismatch was sufficient
to significantly decrease AON efficacy, and (c) found potential correlations between efficacy and some
of the parameters analyzed. Overall, our results show that AON-based splicing modulation holds
great potential for treating Stargardt disease caused by splicing defects in ABCA4.
Keywords: antisense oligonucleotides; Stargardt disease; inherited retinal diseases; splicing modulation;
RNA therapy; ABCA4; iPSC-derived photoreceptor precursor cells
1. Introduction
Stargardt disease (STGD1; MIM:248200) is an autosomal recessive condition affecting the retina,
and was first described in 1909 by the German ophthalmologist Karl Stargardt [1]. The clinical
hallmark of STGD1 is progressive bilateral impairment of central vision. Impairment in visual acuity
and progressive bilateral atrophy of photoreceptors and the retinal pigment epithelium (RPE) are
accompanied by the accumulation of toxic fluorescent deposits of lipofuscin in the macula [2,3].
The underlying genetic causes of the disease are mutations in the ABCA4 gene that encodes the
ATP-binding cassette transporter type 4 subfamily A (ABCA4). The ABCA4 protein belongs to the
superfamily of membrane-bound ATP-binding cassette transporters [4]. It translocates the visual cycle
metabolites, all-trans-retinal and N-retinylidene-phosphatidyl ethanolamine (N-retinylidene-PE), from
the lumen to the cytoplasmic side of photoreceptor disc membranes [5]. The decrease in ABCA4 activity
causes an accumulation of toxic retinal derivatives, which eventually results in RPE and photoreceptor
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cell death [6,7]. Over 900 disease-associated variants in ABCA4 have been described [8,9], causing a
wide range of phenotypes ranging from STGD1 to cone–rod dystrophy, depending on the severity of
the mutation [10,11].
STGD1 cases can be explained by biallelic mutations in either the coding sequence or in the
intronic regions of ABCA4 [12]. Around 10% of cases carry intronic variants that result in the
insertion of pseudoexons (PEs) into the final ABCA4 mRNA transcript [4,9,13–20]. Such mutations
are an ideal target for antisense oligonucleotide (AON) therapy. AONs are short synthetic RNA
molecules that can interfere with the processing of pre-mRNA [21] and thereby modulate splicing.
Modified AONs employed to correct splicing defects have been extensively studied in the field of
inherited retinal diseases (IRDs) for genes such as CEP290 [22–27], USH2A [28], CHM [29], OPN1 [30],
or ABCA4 [18,20,31]. The first splicing modulation strategy described for a retinal disease was targeting
a recurring deep-intronic variant (c.2991+1655A>G) in the CEP290 gene, underlying recessive Leber
congenital amaurosis (LCA; MIM:611755). This mutation results in the generation of a cryptic splice
donor site leading to a 128-nt pseudoexon with a premature stop codon between exons 26 and 27.
AONs used to block the pseudoexon showed successful restoration of the original mRNA both in vivo
and in vitro [22,24–27] and have recently shown promising results in the first clinical trial with AONs
for IRDs [32].
Another mutation that causes a pre-mRNA splicing defect and is amenable to AON therapy is the
c.4539+2001G>A variant in ABCA4 [13–15], which is recurrently found in the Belgian and Dutch STGD1
population. Recently, our group described the molecular mechanism by which c.4539+2001G>A
and the adjacent c.4539+2028C>T mutations in ABCA4 lead to insertion of a retina-specific 345-nt
pseudoexon that is predicted to result in premature termination of protein synthesis (p.Arg1514Leufs*36).
The c.4539+2001G>A variant enhances a predicted exonic splice enhancer and creates a new SRp55
motif. This was the first reported insertion of a pseudoexon into a retinal gene due to the creation of new
exonic splicing enhancer (ESE) motifs rather than the generation of new cryptic splice sites, although
other examples have been described previously [33,34]. By using AON technology, we were able to
restore correct splicing with two of the four AONs (AON1–4) that were used (AON1 and AON4) [18].
In this study, we performed an in-depth screening of a large set of AONs targeting the entire
pseudoexon region to identify the most effective AON(s) against the splicing defect caused by the
c.4539+2001G>A mutation. In total, 26 AONs were screened in retinal precursor cells differentiated
from patient-derived induced pluripotent stem cell (iPSC), and their efficacy in correcting splicing
defects was assessed. Subsequently, properties of the most effective AONs were compared in order to
identify potential parameters for a better design of AONs in the future.
2. Materials and Methods
2.1. Study Design
The objectives of this study were to (1) perform an in-depth screening of AONs targeting the
pseudoexon introduced by the recurrent c.4539+2001G>A deep-intronic variant in ABCA4, (2) identify
the best AON(s) to correct the pre-mRNA splicing defect caused by this mutation using patient-derived
photoreceptor precursor cells (PPCs), and (3) identify potential correlations between AON characteristics
and their efficacy that can provide new insights into a better AON design. Twenty-two new AONs
targeting the pseudoexon were designed and tested together with four previously described AONs [18].
Fibroblast cells obtained from a skin biopsy of a Stargardt individual carrying the deep-intronic variant
were cultured, reprogrammed into iPSCs, and subsequently differentiated to PPCs. All 26 AONs
and two sense oligonucleotides (SONs) were designed along the pseudoexon. Upon AON delivery,
subsequent RNA analysis by RT-PCR was performed to assess the efficacy of the splicing redirection
for each AON. After semiquantification of the rescue, AONs were classified into different groups, and
the properties of the AONs were compared to identify parameters that could improve the AON design.
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Two separate differentiation experiments were performed. RNA analysis was performed in triplicate
to reduce technical variability.
2.2. AON Design
Previously, four AONs were designed targeting the top SC35 motifs and the mutation itself [18].
For the detailed screening that was the subject of this study, the entire pseudoexon plus the flanking
regions were analyzed for their RNA structure to identify the open and closed regions. Subsequently,
AONs were designed according to previously described guidelines independently of the potential
motifs that they were targeting [35,36]. All AON sequences and properties are provided in Table 1.
After AON design, targeted regions were analyzed to predict potential exonic splicing enhancer
(ESE) motifs using either an ESE finder (http://krainer01.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?
process=home), which allows for the detection of SRSF1, SRSF2, SRSF5, and SRSF6, or using RBPmap
(http://rbpmap.technion.ac.il/index.html), which allows for the identification of 94 potential binding
sites for RNA binding proteins. All AONs were 2’OMe-PS (2’O-methyl phosphorothioate) and were
purchased from Eurogentec (Liege, Belgium). Sequences and general parameters of the 26 AONs and
2 SONs are depicted in Table 1.
2.3. Subjects
A skin biopsy was collected from a Dutch individual with STGD1 carrying the ABCA4 variants
c.4539+2001G>A (p.Arg1514Leufs∗36) and c.4892T>C (p.Leu1631Pro) to establish a fibroblast cell line,
as described previously [18]. Our research was conducted according to the tenets of the Declaration of
Helsinki and after gathering written informed consent from the STGD1 individual. The procedures for
obtaining human skin biopsies to establish primary fibroblast cell lines were approved by the local
ethical committee (2015-1543).
2.4. iPSC Differentiation into Photoreceptor Precursor Cells (PPCs)
Fibroblast cells were reprogrammed into iPSCs, as previously described [18]. PPCs were obtained
after following a 2D differentiation protocol [37]. Briefly, iPSCs were dissociated with ReLeSR (Stemcell
Technologies) and plated in 12-well plates coated with matrigel (Corning, Tewksbury, MA, USA) to form
a monolayer. Essential-Flex E8 medium was changed to differentiation medium (CI) when reaching
confluence. The CI medium consisted of DMEM/F12 supplemented with nonessential amino acids
(NEAA, Sigma Aldrich, Saint Louis, CA, USA), B27 supplements (Thermo Fisher Scientific, Waltham,
MA, USA), N2 supplements (Thermo Fisher Scientific), 100 ng/µL of insulin growth factor-1 (IGF-1,
Sigma Aldrich), 10 ng/µL of recombinant fibroblast growth factor basic (bFGF, Sigma Aldrich), 10 µg/µL
of Heparin (Sigma Aldrich), 200 µg/mL of recombinant human COCO (R&D Systems, Minneapolis,
MN, USA), and 100 µg/mL of Primocin (Invivogen, Toulouse, France). Half of the medium was replaced
every day for 30 days. On day 28, PPCs were treated with 1 µM of AON. AONs were first mixed with
the medium without any transfection reagent and were subsequently added to the cells. Twenty-four
hours later, cycloheximide (CHX) was added to the medium (final concentration 100 µg/mL), and on
day 30 (48 h post-AON delivery and 24 h post-CHX treatment), cells were collected.
2.5. RNA Analysis
RNA was isolated from patient-derived PPCs using the Nucleospin RNA kit (Machery Nagel,
Düren, Germany) following the manufacturer’s instructions. One microgram of total RNA was used for
cDNA synthesis using SuperScript VILO Master Mix (Thermo Fisher Scientific) and was subsequently
diluted with H2O to a final concentration of 20 ng/µL. Reverse transcription-PCR (RT-PCR) was
performed with 10 µM of each primer, 2 µM of dNTPs, 2.5 mM of MgCl2, 1 U of Taq polymerase
(Roche, Basel, Switzerland), and 80 ng of cDNA in a total reaction of 25 µL using the following PCR
conditions: 2 min at 94 ◦C, followed by 35 cycles of 30 s at 94 ◦C, 30 s at 58 ◦C, and 70 s at 72 ◦C, with a
final extension of 2 min at 72 ◦C. Actin was amplified to serve as a loading control. All PCR products
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were resolved on 2% agarose gels and were confirmed by Sanger. Fiji software was used to perform a
semiquantitative analysis of the bands in which the values were normalized against the housekeeping
gene ACTB [38]. For that, the band representing the 345-nt pseudoexon, plus half of the value of the
heteroduplexes, and the partial pseudoexon skipping band were counted as aberrant. The other half
of the heteroduplexes together with the correct band were considered to be correct transcripts. We
observed a nonspecific band that was not considered for the analysis. The list of primers is provided in
the Supplementary Materials, Table S1.
2.6. qPCR
The cDNA samples were obtained as described above from iPSCs at day 0, and the nontreated PPCs
at day 30 (both replicates) were used for quantitative real-time PCR (qPCR) to assess the differentiation
process: qPCR was performed using GoTaq qPCR master mix (Promega, Madison, WI, USA). Three
technical replicates were done for each of the two biological replicates. The list of primers is provided
in the Supplementary Materials, Table S1.
2.7. AON Classification and Common Properties
Once the rescue was assessed, AONs were classified into 5 groups: Highly effective (>75%
correction), effective (between 75% and 50%), moderately effective (between 50% and 25%), poorly
effective (between 25% and 0%), and noneffective (no correction detected). For the study of the
properties of each group, the groups poorly effective and noneffective were combined into one single
group, as well as the highly effective and effective groups, generating three new groups: Effective,
moderately effective, and poorly effective. Using this information, several potential correlations
between AON properties, target motifs, and their efficacy were assessed, with the aim of establishing
possible improvements in the AON design. Statistical analyses were performed using GraphPad
Prism. Given the low numbers for some of the groups, normality could not be assessed, and therefore
nonparametric tests were used.
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Table 1. Antisense oligonucleotide (AON) sequences and general parameters.
AON# Sequence (5′to 3′) L Tm GC FE-A FE-D BE Remarks
AON1 ACAGGAGUCCUCAGCAUUG 19 51.1 53 −0.1 −12.4 16.2 Specific for c.4539+2001G>A-pseudoexonPreviously reported in Reference [18]
AON2 UUUUGUCCAGGGACCAAGG 19 51.1 53 −1.6 −15.6 23.1 Previously reported in Reference [18]
AON3 CUGUUACAUUUUGUCCAGG 19 46.8 42 −0.9 −7.3 20.7 Previously reported in Reference [18]
AON4 GGGGCACAGAGGACUGAGA 19 55.4 63 −0.8 −5.9 30.6 Previously reported in Reference [18]
AON5 GAGAGAAAAUAUUGCUUGAGAA 22 47.4 32 1.7 −5.0 27.5
AON6 GCAGAUGAGCUGUGAUUCAA 20 49.7 45 −2.5 −8.8 24.0
AON7 UAUGAUGCAGCAGAUGAGCUG 21 52.4 48 −3.9 −12.2 24.1
AON8 UGGGAUCCCUAUGAUGCAGC 20 53.8 55 −1.1 −17.4 19.4
AON9 AGAGGACUGAGACAAGUUCC 20 51.8 50 −4.2 −10.0 23.1
AON10 GCUUCCUCUUGGGGCACAGA 20 55.9 60 −5.1 −12.0 28.4
AON11 CCUCAGCAUUGACAGCAA 18 48 50 −0.6 −3.2 16.1
AON12 ACAGGAGCCCUCAGCAUUG 19 53.2 58 −0.4 −9.3 11.1 One mismatch in c.4539+2001G>A-pseudoexon
AON13 UGGAGGCAGCCACAGGAG 18 54.9 67 −1.3 −11.8 31.4
AON14 GAUGCUGGAGGGUUUUGAGUG 21 54.4 52 −1.7 −12.6 27.1 One mismatch in c.4539+2028C>T-pseudoexonPerfect match in c.4539+2001G>A-pseudoexon
AON15 GAUGCUGGAGAGUUUUGAGUG 21 52.4 48 −1.7 −14.2 20.2 Specific for c.4539+2028C>T-pseudoexonOne mismatch in c.4539+2001G>A-pseudoexon
AON16 GCCUUGACGUCCUGAUGCU 19 53.2 58 1.4 −10.3 20.4
AON17 GCCAAGAGCUCAGGGUACAG 20 55.9 60 −0.9 −19.9 31.8
AON18 CUUGGCCUCCCCUCCCUC 18 57.2 72 1.4 −8.3 29.4
AON19 AACACCAUGUAGGUAGGC 18 48 50 −1.6 −6.8 21.2
AON20 GUUUAGGAAAUGAAACACCAUG 22 49.2 36 −0.7 −4.5 23.0
AON21 GACCGCGUGGAAGUAAGG 18 52.6 61 −0.3 −14.9 22.1
AON22 AUAAGUUUCUAAGCUGGACAG 21 48.5 38 −0.4 −8.1 27.2
AON23 GGACCAAGGACCAACACUAC 20 53.8 55 −0.6 −9.7 27.9
AON24 GGCUGUUACAUUUUGUCCAGG 21 52.4 48 −1.0 −7.5 28.5
AON25 GGCAGGAACUGGCUUGCCUU 20 55.9 60 −8.6 −20.2 27.2
AON26 AGAAGUGAAAGAAAAUGGCAGG 22 51.1 41 1.9 −3.0 23.3
SON1 CAAUGCUGAGGACUCCUGU 19 51.1 53 −0.7 −11 6.0 Sense sequence of AON1Previously reported in Reference [18]
SON2 UCUCAGUCCUCUGUGCCCC 19 55.4 63 −0.9 −5.6 3.4 Sense sequence of AON4
The nucleotides underlined represent the possible mismatch in relation to the mutation present in the pseudoexon (c.4539+2001G>A or c.4539+2028C>T). L: Length in nt; Tm: Melting
temperature in ◦C; GC: GC content in %; FE-A: Free energy AON molecule; FE-D: Free energy AON dimer; BE: Binding energy to the target region. All energy values are in arbitrary units
obtained using RNAstructure software (https://rna.urmc.rochester.edu/RNAstructureWeb/Servers/bifold/bifold.html).
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3. Results
Previously, we showed that the variants c.4539+2001G>A and c.4539+2028C>T cause the insertion
of a 345-nt pseudoexon in a retina-specific manner. Four AONs (AON1 to AON4) targeting this
region were designed according to previously described guidelines [35,36,39] and were assessed in
PPCs. Our results showed that two AONs (AON1 and AON4) were able to restore correct ABCA4
splicing by skipping the pseudoexon in a mutation-dependent manner. AON1 was specific for the
c.4539+2001G>A variant and was not able to correct the splicing defect caused by the c.4539+2028C>T
mutation, suggesting that one nucleotide mismatch can already impair rescue efficacy. Here, we
screened the entire pseudoexon region in order to identify potential new targets that can promote
splicing redirection with a higher efficacy by designing 22 new AONs.
3.1. Screening and Selection of AONs
The entire pseudoexon (345 nt) together with its flanking regions were subjected to AON design.
A total of 22 new AONs were designed throughout the entire region (Figure 1A). The AON design
parameters, such as melting temperature (Tm), GC content, and free energy were assessed in order
to have optimal sequences when possible (e.g., Tm > 48 ◦C, GC content between 40% and 60%).
Subsequently, to further assess what AONs were targeting, we predicted the RNA structure of the
region using mfold software [40]. We also checked the ESE motifs that were present in the region
using an ESE finder (http://rulai.cshl.edu/) or the potential RNA binding protein sites using RBPmap
(http://rbpmap.technion.ac.il/). Overall, all AONs were covering the pseudoexon or its splice sites and
were targeting all types of regions (predicted to be more closed or open) and motifs.
Patient-derived iPSCs heterozygously carrying the c.4539+2001G>A mutation in conjunction
with another ABCA4 mutation on the other allele were differentiated into PPCs. Differentiation of the
cells was assessed by qPCR. The results showed a differentiation toward retinal lineage with a clear
increase in ABCA4 expression (Supplementary Materials, Figure S1). As we already described, the
345-nt pseudoexon was only visible upon inhibition of nonsense-mediated decay (NMD) (Figure 1B).
Therefore, PPCs were first treated with the corresponding AON and after 24 h were subjected to
cycloheximide (CHX) treatment to inhibit NMD. RNA analysis was performed by RT-PCR (Figure 1B).
We then semiquantified the amount of aberrant transcript (Figure 1C). Remarkably, three AONs were
able to almost completely rescue the splicing defect (AON4, AON17, and AON18). Interestingly,
we also observed that four AONs (AON7, AON13, AON14, and AON16) caused the appearance of
additional bands. Some of them represented partial pseudoexon skipping, while others turned out to
be potential artifacts due to mis-splicing, although we could not exactly determine the splicing sites.
Sequencing results determined that the partial-exon skipping observed in AON14 and AON16-treated
samples was a partial skipping of exon 30 (previously described in Reference [18]) together with
partial skipping of the first 142 nt of the pseudoexon (splice acceptor site in c.4539+2035). In the
case of AON13, we identified partial pseudoexon exclusion, but we could not determine the splice
acceptor site. In the case of AON7, we could not determine both splice sites (acceptor and donor), and
it was probably an aberrant mRNA caused by the AON treatment. Using the average of the cells not
treated with AONs but subjected to CHX treatment and the ones treated with the sense oligonucleotide
(SON), we established the basal levels (~29%) of the ABCA4 aberrant transcript (Figure 1C). These
values were used to establish the percentage of correction for each AON (Figure 2A). Five groups were
determined: Highly effective (correction >75%, n = 3), effective (75%–50%, n = 6), moderately effective
(50%–25%, n = 8), poorly effective (25%–0%, n = 9), and noneffective (0% or even increasing the amount
of pseudoexon). These groups are depicted in Figure 2A according to different colors in the graph.
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observed in all samples, containing the correct and the pseudoexon-included transcripts. 
AON-derived partial skipping was observed in samples AON14 and AON16. Double bands 
highlighted with an * (lanes AON7 and AON13) indicate artifacts derived from the AON treatment, 
and splice sites could not be identified upon Sanger sequencing. In most of the lanes, we identified a 
PCR artifact (nonspecific band). (C) Percentage of aberrant transcript after semiquantification. NT: 
Nontreated; CHX: Cycloheximide. Error bars indicate average ± SD. 
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treatment. ACTB was used to normalize samples. An heteroduplex band was observed in all samples,
containing the correct and the pseudoexon-included transcripts. AON-derived partial skipping was
observed in samples AON14 and AON16. Double bands highlighted with an * (lanes AON7 and
AON13) indicate artifacts derived from the AON treatment, and splice sites could not be identified upon
Sanger sequencing. In most of the lanes, we identified a PCR artifact (nonspecific band). (C) Percentage
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3.2. Analysis of the Properti s of the AONs
Once th efficacy of all AONs was estimat , subdivided them in o three lar er groups:
Effective (n = 9 comprising all AONs with an efficacy > 50%), moderately effective (n = 8 with efficacies
between 25% and 50%), and poorly effective (n = 7, the rest). AONs containing a mismatch (AON12
and AON15) were not used in these analyses, as the decrease in the efficacy was due to the mismatch.
This was shown by the fact that both AON1 and AON14 (perfectly matching the c.4539+2001G>A
allele, but containing a mismatch for the PE induced by the c.4539+2028C>T mutation) correct the
splice defect associated with c.4539+2001G>A.
We first analyzed the basic parameters: Melting temper ture (Tm), GC content, and length
(Figure 2B). We found a statistically significant correlation (two-tailed Spearman test) for the Tm and
GC content parameters (p = 0.0012 and p = 0.0041, respectively). In both cases, the higher the value
was, the more efficient the AON was (Supplementary Materials, Figure S2). The Tm average of the
three groups ranged from 54.21 ◦C (effective) to 50.19 ◦C (poorly effective). The differences in Tm
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between groups was statistically different (p = 0.0292, nonparametric one-way ANOVA), while the GC
content was nearly significant (p = 0.0611). When comparing all different groups separately, statistically
significant differences were observed between the groups of effective AONs and poorly effective AONs
for Tm (p = 0.0256, Mann–Whitney test) and GC content (p = 0.0127). No differences were observed for
the length of the AONs.
Other important parameters when designing AONs are the free energy of the AON molecule
itself, the dimer, and the binding energy to the target. The free energy of the AON molecule and its
dimer did not show any correlation nor difference between groups. Interestingly, the binding energy
showed a significant correlation (p = 0.0391) with efficacy. We analyzed the groups separately, and
although no statistically significant differences were found, the effective group showed a trend toward
significance when compared to the moderately effective (p = 0.0673, Mann–Whitney test) and the
poorly effective (p = 0.0712, Mann–Whitney test) groups. Consistently, the highest binding energies
corresponded to the three most effective AONs (AON4, AON17, and AON18). Interestingly, when
these three values were separated, the tendency of the effective group disappeared. In contrast, these
three AONs only showed a statistically significant higher binding energy compared to the other three
groups (Figure 2C).
Next, we checked the common serine and arginine-rich splicing factors (SRSFs): SF2 (SRSF1),
SC35 (SRSF2), SRp40 (SRSF4), and SRp55 (SRSF5)) using an ESE finder (Supplementary Materials,
Figure S3). All motifs that were partially or completely covered by an AON were counted and assigned
to the particular AON. We did not find any correlation between the percentage of correction and the
presence of these motifs. However, we noticed that the strength of some of the motifs was different
between groups. For that, we categorized all the motifs found by assigning them a number according
to the strength of the predicted score (lowest = 1, second lowest = 2, etc.). After that, the average for
each AON was calculated. Interestingly, a statistically significant correlation (p = 0.0066, two-tailed
Spearman test) was observed for the categorized SRp40 motifs. In this case, the strongest motifs were
correlating with the poorly or moderately effective AONs, and the lowest with the effective ones
(Figure 2D). However, when pooling all groups together, differences were not statistically significant.
No other differences were detected for any of the other three SRSF motifs, except for SC35, where
significant differences were observed when comparing effective versus moderately effective AONs
(p = 0.0316, Mann–Whitney test; Supplementary Materials, Figure S3).
Finally, we used RBPmap to predict potential RNA protein-binding motifs. Again, each motif
detected in the region was assigned to each AON when partial or complete overlap occurred. First,
manual filtering of the motifs was done by checking which motifs were common to all AONs in
each group. Unfortunately, none of the motifs were shared between all effective AONs. AON18
was the one behaving differently than the rest, almost not sharing any motif with the others. When
AON18 was left out of the filtering, SRSF3 appeared as a common motif not only in the effective group,
but also in the poorly and moderately effective groups. When assessed in more detail (Figure 2D),
a statistically significant negative correlation was observed (p = 0.0188, two-tailed Spearman test).
The analysis per group revealed a significant difference between the effective and poorly effective
groups (p = 0.0431) and close to significance between the moderately and poorly effective groups
(p = 0.0622). Categorized SRSF3 did not show significant differences. The second most recurrent motif
in the poorly effective group was MBNL1. Given the fact that all but one poorly acting AON contained
this predicted motif, we performed statistical analyses to determine whether the presence of MBNL1
motifs correlated with the lower performance of some AONs. Indeed, a significant correlation was
observed (p = 0.0025), implying an association between the presence of these motifs and a low AON
performance (Figure 2D). When differences between groups were assessed, only the effective group
showed a statistically significant lower number of MBNL1 when compared to the poorly effective
group (p = 0.0309). The total amount of motifs detected by RBPmap showed a nearly significant
negative correlation with efficiency (p = 0.0522). However, when groups were analyzed separately, this
trend completely disappeared (Supplementary Materials, Figure S4).
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Genes 2019, 10, 452 10 of 14
4. Discussion
The fact that the eye is an isolated, immunoprivileged, and easily accessible organ makes it a
very attractive model for molecular therapies. In addition, IRDs are progressive diseases that offer a
window of opportunity for treatment. However, the high genetic heterogeneity in IRDs hampers the
development of new therapies. AONs have been shown to be an auspicious approach to treat splicing
defects causing IRDs. They have been shown to be safe and easy to deliver to the retina without
the necessity of any vector. Furthermore, recent results from a phase 1/2 clinical trial to correct the
splicing defect introduced by a deep-intronic mutation in CEP290 showed the great potential that these
molecules hold. In this study, we screened 26 AONs targeting a pseudoexon product of a recurrent
deep-intronic mutation (c.4539+2001G>A) in the ABCA4 gene with the intention of identifying the
most promising AON molecules to eventually treat STGD1.
We designed and tested 26 different AONs located across the 345-nt pseudoexon. In total, three
highly effective AONs were identified: AON4, AON17, and AON18. All of them showed similar
efficacies (76.42%–76.97%). Another six AONs (AON1, AON9, AON10, AON14, AON23, and AON24)
corrected the pre-mRNA splicing defect with an efficacy of more than 50%. Previously, we showed that
AON1 was only effective when the change c.4539+2001G>A was present, as the pseudoexon containing
the change c.4539+2028C>T was not removed. This highlighted the fact that for 2’OMe/PS chemically
modified AONs, one mismatch could dramatically affect the splicing redirection efficacy. Here, we
demonstrated again that one mismatch was enough to prevent AON-based splicing modulation.
For that, we generated the same AON1 but with a wild-type nucleotide (AON12). Furthermore,
we also designed an AON specific for the c.4539+2028C>T variant (AON15) and a corresponding
AON with a wild-type change (AON14). As expected, the mutation-specific AON (AON15) did not
redirect splicing in this cell line, while the one perfectly matching the target did (AON14). Interestingly,
AON14, although its correction efficacy was around 50%, is not considered a very promising AON for
future studies since it was one of the four AONs (together with AON7, AON13, and AON16) that
showed novel aberrant bands in RT-PCR. In this particular case, both AON14 and AON16 caused an
unexpected (AONs binding on top of the novel splice acceptor site at position c.4539+2035) partial
pseudoexon exclusion together with an already described partial exon 30 skipping [18]. However,
this was clearly induced by these two AONs, which bind in the same region. However, for AON7
and AON13, we were not able to determine how the aberrant band was generated due to the lack of
predicted splicing sites, and therefore we considered them artifacts. We previously observed a similar
effect for another variant, and we concluded that this was either a PCR artifact or, due to the fact
that AONs can interfere with RNA structure and the splicing machinery, some aberrant mis-spliced
transcripts that may have appeared [20].
After classifying the AONs into three groups, we tried to identify common properties that could
eventually lead to a better AON design. When analyzing the groups, we found correlations with the
Tm and the GC content. Previously published guidelines [35,36,39] have indicated that Tm should be
above 48 ◦C and the GC content between 40% and 60%. Based on our analyses, it seems that if the
temperature is higher than 51 ◦C and the GC content close to 60%, the chances of designing an AON
with a good efficacy are higher. According to previous guidelines, the binding energy should stay
between 21 and 28. However, our best AON molecules had binding energies to the target of more
than 30. Moreover, based on correlations that we were able to identify, AONs targeting predicted
SRSF3 or MBNL1, as well as strong predicted SRp40 motifs, might show poorer efficacies. Although
some of these parameters have been shown before to be relevant to AON design, it is important to
mention that the efficacy of an AON molecule also can depend on the type of cell, tissue, or organ.
In that sense, the parameters established above might be valid only for AONs delivered to retinal
cells, and further confirmation in cells of other origins needs to be addressed. Unfortunately, this
comparison was not possible in our case due to the fact that although ABCA4 is lowly expressed in
fibroblast cells, the splicing defects observed for some mutations, including c.4539+2001G>A, are not
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recapitulated in those cells. Most probably this is because the splicing retinal machinery may have
different efficacies or recognition sites [41,42].
In our previous studies, AON1 showed an efficacy of ~75% [18]. However, in this study, only
~51% correction was detected, although the PPCs were derived from the same patient iPSC line. One
explanation could be that in our previous study, we only detected around 25% of pseudoexon insertion,
while in this study we were able to detect more pseudoexon-including transcripts (~30%). This could
therefore have modified the correction ratio. In addition, the inhibition of NMD by CHX is not always
complete, and therefore variability in the detection of the pseudoexon transcript (subjected to NMD)
might have been variable between experiments and samples. Another possible explanation could be
differences between the AON batches. All of these factors, either alone or in combination, could have
influenced the differences observed between the two studies.
Finally, as discussed above, AON4, AON17, and AON18 showed the highest efficacies. However,
AON18 did not show that much similarity to the other two AONs other than a high binding energy.
AON18 did not share obvious targeted predicted motifs with either of the two highly effective AONs
(Supplementary Materials, Figure S5). We also checked the secondary structure of the RNA and all
three AON target partially closed regions. Therefore, the slightly higher efficacy might have been
related to the binding to the target itself and the disruption of the secondary structure rather than the
motifs that were blocked by the molecule. In addition, when comparing the sequences to see which one
could be a potential candidate for further development, we observed that all three AONs contained
stretches of Gs and Cs (which are recommended to be avoided). AON4 and AON17 contained a G
stretch of four and three Gs, respectively, while AON18 contained two stretches of three and four Cs.
Nevertheless, given their efficacy, all three molecules might be potential good candidates for further
therapeutic studies.
5. Conclusions
In conclusion, we designed 26 AONs targeting a 345-nt pseudoexon caused by the recurrent
c.4539+2001G>A deep-intronic mutation in ABCA4. In total, nine AONs showed promising efficacies
(correction above 50%). We identified three AONs promoting a correction superior to 75%. For AON
design, we suggest increasing the minimum Tm to 50 or 51 ◦C, the GC content close to 60%, and
the binding energy to around 30 to target retinal pseudoexons, although this needs to be tested and
confirmed using other targets. Overall, we demonstrated that AON-based splicing modulation holds
great potential for treating Stargardt disease caused by splicing defects in ABCA4.
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